We intend to expand our existing tissue culture and animal-based infrastructure on the way that it can continually be able to isolate larger amount of antibodies several times a year, from the hybridomas created by its own earlier development or from the cells obtained from the academic and the industrial partners.

The antibodies produced are marketed in various technical solutions and can be used as laboratory diagnostic kits, molecular biology reagents, for immunohistochemical techniques, etc.